Skip to content
1887
  1. Home
  2. A-Z Publications
  3. Johnson Matthey Technology Review
  4. Volume 61, Issue 1
  5. Article
Volume 61, Issue 1
  • ISSN: 2056-5135
file format pdf download PDF

Abstract

A literature based study on the health impacts of three platinum anticancer drugs (cisplatin, carboplatin and oxaliplatin) was undertaken. The published evidence for health benefits is presented and assessed. A model was developed to quantify the health gain of adding platinum based drugs to cancer treatment at the population level for the UK and the USA. The economic value of using platinum drugs (in terms of quality-adjusted life year (QALY)) in addition to other cancer treatments can be estimated at over £556 million for the UK and over US$4.8 billion for the USA, depending on the scenario chosen.

© Johnson Matthey
Loading

Article metrics loading...

/content/journals/10.1595/205651317X693741
2017-01-01
2024-05-03
Loading full text...

Full text loading...

/deliver/fulltext/jmtr/61/1/JMTR-61-1-Filby.html?itemId=/content/journals/10.1595/205651317X693741&mimeType=html&fmt=ahah

References

  1. “Developing NICE Guidelines: The Manual”, Process and Methods, PMG20, National Institute for Health and Care Excellence, London, UK, October, 2014 LINK https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview
  2. ‘Appraising Life-Extending, End of Life Treatments’, National Institute for Health and Clinical Excellence, London, UK, 2009 LINK https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2
  3. National Institute for Health and Care Excellence (NICE), British National Formulary (BNF), ‘Platinum Compounds’, October, 2016:https://www.evidence.nhs.uk/formulary/bnf/current/8-malignant-disease-and-immunosuppression/81-cytotoxic-drugs/815-other-antineoplastic-drugs/platinum-compounds (Accessed on 10th November 2016)
  4. Wallace D. M. A., Raghavan D., Kelly K. A., Sandeman T. F., Conn I. G., Teriana N., Dunn J., Boulas J., and Latief T. British J. Urology, 1991, 67, (6), 608 LINK http://dx.doi.org/10.1111/j.1464-410X.1991.tb15225.x [Google Scholar]
  5. Smit E. F., Burgers S. A., Biesma B., Smit H. J. M., Eppinga P., Dingemans A.-M. C., Joerger M., Schellens J. H., Vincent A., van Zandwijk N., and Groen H. J. M. J. Clin. Oncol., 2009, 27, (12), 2038 LINK http://dx.doi.org/10.1200/JCO.2008.19.1650 [Google Scholar]
  6. Ardizzoni A., Tiseo M., Boni L., Vincent A. D., Passalacqua R., Buti S., Amoroso D., Camerini A., Labianca R., Genestreti G., Boni C., Ciuffreda L., Di Costanzo F., de Marinis F., Crinò L., Santo A., Pazzola A., Barbieri F., Zilembo N., Colantonio I., Tibaldi C., Mattioli R., Cafferata M. A., Camisa R., and Smit E. F. J. Clin. Oncol., 2012, 30, (36), 4501 LINK http://dx.doi.org/10.1200/JCO.2012.43.6758 [Google Scholar]
  7. Muggia F. M., Braly P. S., Brady M. F., Sutton G., Niemann T. H., Lentz S. L., Alvarez R. D., Kucera P. R., and Small J. M. J. Clin. Oncol., 2000, 18, (1), 106 LINK http://ascopubs.org/doi/full/10.1200/JCO.2000.18.1.106 [Google Scholar]
  8. Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., MacLean G., Souhami L., Stuart G., and Tu D. J. Clin. Oncol., 2002, 20, (4), 966 LINK http://ascopubs.org/doi/full/10.1200/jco.2002.20.4.966 [Google Scholar]
  9. Garipağaoğlu M., Kayikçioğlu F., Köse M. F., Adli M., Gülkesen K. H., Koçak Z., and Tulunay G. British J. Radiol., 2004, 77, (919), 581 LINK http://dx.doi.org/10.1259/bjr/63967203 [Google Scholar]
  10. Chiara S., Bruzzone M., Merlini L., Bruzzi P., Rosso R., Franzone P., Orsatti M., Vitale V., Foglia G., Odicino F., Ragni N., Rugiati S., and Conte P. Am. J. Clin. Oncol., 1994, 17, (4), 294 LINK http://dx.doi.org/10.1097/00000421-199408000-00003 [Google Scholar]
  11. Ghadjar P., Simcock M., Studer G., Allal A. S., Ozsahin M., Bernier J., Töpfer M., Zimmermann F., Betz M., Glanzmann C., and Aebersold D. M. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82, (2), 524 LINK http://dx.doi.org/10.1016/j.ijrobp.2010.11.067 [Google Scholar]
  12. Ibrahim A., Hirschfeld S., Cohen M. H., Griebel D. J., Williams G. A., and Pazdur R. The Oncologist, 2004, 9, (1), 8 LINK http://dx.doi.org/10.1634/theoncologist.9-1-8 [Google Scholar]
  13. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., and Bonetti A. J. Clin. Oncol., 2000, 18, (16), 2938 LINK http://ascopubs.org/doi/full/10.1200/jco.2000.18.16.2938 [Google Scholar]
  14. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., Chollet P., Llory J. F., Letourneau Y., Coudert B., Bertheaut-Cvitkovic F., Larregain-Fournier D., Le Rol A., Walter S., Adam R., Misset J. L., and Lévi F. J. Clin. Oncol., 2000, 18, (1), 136 LINK http://ascopubs.org/doi/full/10.1200/jco.2000.18.1.136 [Google Scholar]
  15. Hospers G. A. P., Schaapveld M., Nortier J. W. R., Wils J., van Bochove A., de Jong R. S., Creemers G. J., Erjavec Z., de Gooyer D. J., Slee P. H. Th. J., Gerrits C. J. H., Smit J. M., and Mulder N. H. Ann. Oncol., 2006, 17, (3), 443 LINK http://dx.doi.org/10.1093/annonc/mdj104 [Google Scholar]
  16. Kemeny N., Garay C. A., Gurtler J., Hochster H., Kennedy P., Benson A., Brandt D. S., Polikoff J., Wertheim M., Shumaker G., Hallman D., Burger B., and Gupta S. J. Clin. Oncol., 2004, 22, (23), 4753 LINK http://ascopubs.org/doi/full/10.1200/JCO.2004.03.119 [Google Scholar]
  17. Damjanovic D., Thompson P., and Findlay M. P. ANZ J. Surg., 2004, 74, (9), 781 LINK http://dx.doi.org/10.1111/j.1445-1433.2004.03148.x [Google Scholar]
  18. Rothenberg M. L., Oza A. M., Bigelow R. H., Berlin J. D., Marshall J. L., Ramanathan R. K., Hart L. L., Gupta S., Garay C. A., Burger B. G., Le Bail N., and Haller D. G. J. Clin. Oncol., 2003, 21, (11), 2059 LINK http://ascopubs.org/doi/full/10.1200/JCO.2003.11.126 [Google Scholar]
  19. Nafees B., Stafford M., Gavriel S., Bhalla S., and Watkins J. Health Qual. Life Outcomes, 2008, 6, 84 LINK http://dx.doi.org/10.1186/1477-7525-6-84 [Google Scholar]
  20. Greving J. P., Vernooij F., Heintz A. P. M., van der Graaf Y., and Buskens E. Gynecol. Oncol., 2009, 113, (1), 68 LINK http://dx.doi.org/10.1016/j.ygyno.2008.12.008 [Google Scholar]
  21. de Kok I. M. C. M., van Rosmalen J., Dillner J., Arbyn M., Sasieni P., Iftner T., and van Ballegooijen M. Brit. Med. J., 2012, 344, e670 LINK http://dx.doi.org/10.1136/bmj.e670 [Google Scholar]
  22. Greenhalgh J., Bagust A., Boland A., Fleeman N., McLeod C., Dundar Y., Proudlove C., and Shaw R. ‘Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)’, ERG report, National Institute for Health and Clinical Excellence, London, UK, 2008 LINK https://www.nice.org.uk/guidance/ta172/documents/head-and-neck-cancer-squamous-cell-carcinoma-cetuximab-evidence-review-group-report2 [Google Scholar]
  23. Shiroiwa T., Takeuchi T., Fukuda T., Shimozuma K., and Ohashi Y. Value Health, 2012, 15, (2), 255 LINK http://dx.doi.org/10.1016/j.jval.2011.10.006 [Google Scholar]
  24. Heitman S. J., Hilsden R. J., Au F., Dowden S., and Manns B. J. PLoS Med., 2010, 7, (11), e1000370 LINK http://dx.doi.org/10.1371/journal.pmed.1000370 [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.1595/205651317X693741
Loading
Health Impact Analysis of Cisplatin, Carboplatin and Oxaliplatin
Johnson Matthey Technology Review 61, 32 (2017); https://doi.org/10.1595/205651317X693741
/content/journals/10.1595/205651317X693741
/content/journals/10.1595/205651317X693741
Loading

Data & Media loading...

  • Article Type: Research Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error